Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations – Latin America, 2013

World Health Organization. Pan American Health Organization. Department of Family Gender and Life Course/Immunization. Washington, D.C., United States / Université Libre de Bruxelles. Ecole de Santé Publique. Brussels, Belgium.
US Centers for Disease Control and Prevention. Influenza Division. Atlanta, GE, United States.
US Centers for Disease Control and Prevention. Influenza Division. Atlanta, GE, United States.
Múltipla ver em Notas.
Centers for Disease Control and Prevention. San José, El Salvador.
World Health Organization. Pan American Health Organization. Department of Communicable Diseases and Health Analysis. Washington, D.C., United States.
World Health Organization. Pan American Health Organization. Department of Communicable Diseases and Health Analysis. Washington, D.C., United States.
US Centers for Disease Control and Prevention. Influenza Division. Atlanta, GE, United States.
World Health Organization. Pan American Health Organization. Department of Family Gender and Life Course/Immunization. Washington, D.C., United States.

Abstract

Background: Despite widespread utilization of influenza vaccines, effectiveness (VE) has not been routinely measured in Latin America. Methods: We used a case test-negative control design to estimate trivalent inactivated influenza VE against laboratory-confirmed influenza among hospitalized children aged 6 months-5 years and adults aged 60 years which are age-groups targeted for vaccination. We sought persons with severe acute respiratory infections (SARI), hospitalized at 71 sentinel hospitals in Argentina, Brazil, Chile, Colombia, Costa Rica, El Salvador, Honduras, Panama, and Paraguay during January–December 2013. Cases had an influenza virus infection confirmed by real-time reverse transcription PCR (rRT-PCR); controls had a negative rRT-PCR result for influenza viruses. We used a two-stage random effects model to estimate pooled VE per target age-group, adjusting for the month of illness onset, age and preexisting medical conditions. Results: We identified 2620 SARI patients across sites: 246 influenza cases and 720 influenza-negative controls aged 5 years and 448 cases and 1206 controls aged 60 years. The most commonly identified subtype among participants (48%) was the influenza A(H1N1)pdm09 virus followed by influenza A (H3N2) (34%) and influenza B (18%) viruses. Among children, the adjusted VE of full vaccination (one dose for previously vaccinated or two if vaccine naïve) against any influenza virus SARI was 47% (95% confidence interval [CI]: 14–71%); VE was 58% (95% CI: 16–79%) against influenza A(H1N1)pdm09, and 65% (95% CI: 9; 89%) against influenza A(H3N2) viruses associated SARI. Crude VE of full vaccination against influenza B viruses associated SARI among children was 3% (95% CI: 150; 63). Among adults aged 60 years, adjusted VE against any influenza SARI was 48% (95% CI: 34–60%); VE was 54% (95% CI: 37–69%) against influenza A(H1N1)pdm09, 43% (95% CI: 18–61%) against influenza A(H3N2) and 34% (95% CI: 4; 58%) against B viruses associated SARI. Conclusion: Influenza vaccine provided moderate protection against severe influenza illness among fully vaccinated young children and older adults, supporting current vaccination strategies.

Keywords

Influenza
Vaccine effectiveness
Influenza vaccines
Children
Adults
International

DeCS

Influenza Humana
Vacinas contra Influenza
Cobertura Vacinal
Cooperação Internacional
América Latina

Publisher

Elsevier

Citation

EL OMEIRI, Nathalie et al. Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations – Latin America, 2013. Vaccine, [Kidlington], v. 36, p. 3555–3566, 2018.

DOI

10.1016/j.vaccine.2017.06.036

ISSN

0264-410X

Notes

Erica Tatiane da Silva - Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil. Documento produzido em parceria ou por autores vinculados à Fiocruz, mas não consta à informação no documento. A autora é membro do REVELAC-i network.
REVELAC-i network participants: Viviana Sotomayor-Proschle - Ministry of Health of Chile. Santiago, Chile; Natalia Vergara - Ministry of Health of Chile. Santiago, Chile.; Sergio Loayza - Ministry of Health of Chile. Santiago, Chile.; Rodrigo Fasce - Ministry of Health of Chile. Santiago, Chile.; Fernando Muñoz - Ministry of Health of Chile. Santiago, Chile.; Carla Magda S. Domingues – Ministério da Saúde. Brasília, DF, Brasil.; Ernesto Isaac Montenegro Renoiner– Ministério da Saúde. Brasília, DF, Brasil.; Walquíria Aparecida Ferreira de Almeida – Ministério da Saúde. Brasília, DF, Brasil.; Erica Tatiane Da Silva – Ministério da Saúde. Brasília, DF, Brasil.; Martha Von Horoch - Ministry of Health of Paraguay. Asunción, Paraguay.; Cynthia Vazquez - Ministry of Health of Paraguay. Asunción, Paraguay.; Sonia Arza - Ministry of Health of Paraguay. Asunción, Paraguay.; Silvia Battaglia - Ministry of Health of Paraguay. Asunción, Paraguay.; Carla Vizzotti - Ministry of Health of Argentina. Buenos Aires, Argentina.; Elsa Baumeister - Ministry of Health of Argentina. Buenos Aires, Argentina.; Paula Couto - Ministry of Health of Argentina. Buenos Aires, Argentina.; Alejandra Gaiano - Ministry of Health of Argentina. Buenos Aires, Argentina.; Carlos Giovacchini - Ministry of Health of Argentina. Buenos Aires, Argentina.; Juan Hermann - Ministry of Health of Argentina. Buenos Aires, Argentina.; Julián Antman - Ministry of Health of Argentina. Buenos Aires, Argentina.; Teresa Varela - Ministry of Health of Argentina. Buenos Aires, Argentina.; Nathalia Katz - Ministry of Health of Argentina. Buenos Aires, Argentina.; Jacqueline Palacios - Ministry of Health of Colombia. Bogota, Colombia.; Juliana Barbosa - National Health Institute. Bogota, Colombia.; Patricia Salas - National Health Institute. Bogota, Colombia.; Gabriel Camero - The Field Epidemiology Training Program. Colombia.; Viviana Calderón - The Field Epidemiology Training Program. Colombia.; Guiselle Guzmán Saborío - Costa Rican Social Security Fund. San José, Costa Rica.; Fabio Quesada Córdoba - Costa Rican Social Security Fund. San José, Costa Rica.; Antonio García Pérez - Costa Rican Social Security Fund. San José, Costa Rica.; Jenny Lara Araya - Costa Rican Institute of Research and Education in Nutrition and Health. San José, Costa Rica.; Marcela Hernández De Mezerville - Hospital Nacional de Niños. San José, Costa Rica.; Wilberth Alfaro Bourret - Hospital Nacional de Niños. San José, Costa Rica.; Julio Armero - Ministry of Health of El Salvador. San Salvador, El Salvador.; Miguel Elas - Ministry of Health of El Salvador. San Salvador, El Salvador.; Héctor Ramos - Ministry of Health of El Salvador. San Salvador, El Salvador.; Celina de Lozano - Ministry of Health of El Salvador. San Salvador, El Salvador.; Homer Mejía Santos - Ministry of Health of Honduras. Tegucigalpa, Honduras.; Ida Berenice Molina - Ministry of Health of Honduras. Tegucigalpa, Honduras.; María Luisa Matute - Ministry of Health of Honduras. Tegucigalpa, Honduras.; Rudvelinda Rivera - Ministry of Health of Honduras. Tegucigalpa, Honduras.; Itzel Hewitt - Ministry of Health of Panama. Panama City, Panama.; Brechla Moreno -Ministry of Health of Panama. Panama City, Panama.; Yadira De Molto - Ministry of Health of Panama. Panama City, Panama.

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/45709

Type

Copyright

Open access

Sustainable Development Goals

Collections

Share

Statistics

Metadata

Author

Affilliation